IPCA Laboratories

IPCA Laboratories Goodwill/Assets

The Goodwill to Total Assets Ratio of IPCA Laboratories (IPCALAB.NS) as of Nov 13, 2026 is 0.67 %. In the previous year, Goodwill to Total Assets Ratio was 0.77 % — a change of -13.08% (lower).

Goodwill/Assets

0.67 %

YoY

-13.08%

Last updated:

Goodwill to Total Assets Ratio of IPCA Laboratories is 2026 0.67 % . Goodwill to Total Assets Ratio of IPCA Laboratories was 2025 0.77 % . It decreases by -13.08% lower compared to the previous year.

The IPCA Laboratories Goodwill/Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Goodwill/Assets
Date
Goodwill/Assets
Jan 1, 2019
1.04 INR
Jan 1, 2020
1.19 INR
Jan 1, 2021
0.77 INR
Jan 1, 2022
0.51 INR
Jan 1, 2023
0.44 INR
Jan 1, 2024
0.82 INR
Jan 1, 2025
0.77 INR
Jan 1, 2026
0.67 INR
The IPCA Laboratories Goodwill/Assets history
YEARGoodwill/AssetsYoY
0.67 %-13.08%
0.77 %-5.61%
0.82 %+84.55%
0.44 %-13.22%
0.51 %-33.65%
0.77 %-35.31%
1.19 %+14.45%
1.04 %-9.52%
1.15 %-3.83%
1.19 %-1.71%
1.21 %-20.35%
1.52 %+5.86%
1.44 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

IPCA Laboratories Stock analysis

What does IPCA Laboratories do? Ipca Laboratories Ltd. generates revenue through the manufacturing and marketing of over 350 pharmaceutical formulations and approximately 80 active pharmaceutical ingredients (APIs), including Atenolol, Chloroquine Phosphate, Chlorthalidone, Furosemide, Hydroxychloroquine sulfate, Losartan, Metoprolol Succinate, Metoprolol Tartrate, Pyrantel Salts, and Propranolol. The company sells its branded products such as Zerodol, Lariago, HCQS, Perinorm, Rapither AB, Tenoric, Lumerax, Etova, Fexova, Malirid, Allsuth, Alwiz, AZR 50mg, Bacilon, Cinkona, Clarbact, Glyree MV, Halotop, Luliz, Ozepam, Pacimol, Pari, Xtor-F, Zabpro, Zilast, Ramcor, Sove, and Venpower in more than 100 countries globally. Its subsidiaries, Ipca Pharmaceuticals, Inc., Ipca Laboratories (U.K.) Ltd, and Tonira Exports Limited, support the distribution and sales of these products across international markets. The company's primary customers are healthcare providers, hospitals, and pharmacies in over 100 countries, purchasing both generic APIs and branded formulations. Manufacturing units in India produce APIs and formulations, with the firm's subsidiaries facilitating global market access. The therapeutic segments covered by its products include cardiovascular, antimalarial, and gastrointestinal treatments, among others, driven by the demand for cost-effective pharmaceutical solutions. IPCA Laboratories is one of the most popular companies on Eulerpool.

Frequently Asked Questions about IPCA Laboratories stock

Goodwill to Total Assets Ratio of IPCA Laboratories is 0.67 % in 2026.

Goodwill to Total Assets Ratio of IPCA Laboratories changed from 0.77 % to 0.67 %, representing a -13.08% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Goodwill to Total Assets Ratio IPCA Laboratories since 2006 – with annual values, charts, and detailed analysis.

The Goodwill/Assets ratio shows what percentage of total assets consists of acquisition goodwill. High ratios may indicate impairment risk.

Goodwill to Total Assets Ratio's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Goodwill to Total Assets Ratio's IPCA Laboratories historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — IPCA Laboratories

All Key Metrics — IPCA Laboratories